Journal
JOURNAL OF INORGANIC BIOCHEMISTRY
Volume 168, Issue -, Pages 18-26Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2016.12.006
Keywords
Bi(III) complex; Thiosemicarbazones; Anticancer activity; in vivo; Human lung cancer; Drug
Funding
- National Natural Science Foundation of China [21305090, 21401130]
- Laboratory of Analytical Chemistry for Life Science [SKLACLS1502]
- Innovation Program of Shanghai Municipal Education Commission [14YZ086, 14ZZ139]
- Shanghai Natural Science Foundation [13ZR1428300]
- Central Universities
Ask authors/readers for more resources
The aim of this work is experimental study of an interesting bismuth(III) complex derived from pentadentate 2,6-pyridinedicarboxaldehyde bis(N-4-methylthiosemicarbazone), [BiL(NO3)2]NO3 {L = 2,6-pyridinedicarboxaldehyde bis(4N-methylthiosemicarbazone)}. A series of in vitro biological studies indicate that the newly prepared [BiL(NO3)(2)]NO3 greatly suppressed colony formation, migration and significantly induced apoptosis of human lung cancer cells A549 and H460, but did not obviously decrease the cell viability of non-cancerous human lung fibroblast (HLF) cell line, showing much higher anticancer activities than its parent ligands, especially with half maximum inhibitory concentration (IC50) <3.5 mu M. Moreover, in vivo study provides enough evidence that the treatment with [BiL(NO3)(2)]NO3 effectively inhibited A549 xenograft tumor growth on tumor-bearing mice (10 mg kg(-1), tumor volume reduced by 97.92% and tumor weight lightened by 94.44% compared to control) and did not indicate harmful effect on mouse weight and liver. These results suggest that the coordination of free ligand with Bi(III) might be an interesting and potent strategy in the discovery of new anticancer drug candidates. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available